Proprietary 5M-AI Biomarker Approach>
RADR (Rescue Algorithm for Drug Repurposing)>
RADR Identifies abandoned clinical trial drugs that could be rescued and repurposed.
RADR analyzes patient clinical trial data consisting of drug efficacy, toxicity, MOA, and comparisons with disease signatures and approved drug signatures from reference data sets to predict drugs that could have a potential to be used in certain patients.
IROFULVEN-1 FROM AFC LLC
-Inhibitor of RNA Polymerase II, essential enzyme for TCR and Topoisomerase 1 enzymes
-More than 38 phase I, phase II trials; > 1300 patients
-OUT-Licensed to OV
TAVOCEPT FROM BIO-NUMERIK INC
-LP300 is a multi-targeted agent
-In phase I, phase II trials; > 600 patients
-Lantern is currently analyzing signature for drug response
IROFULVEN-2 FROM AFC LLC
-Next Gen Irofulven
-10x Improved Efficacy and Less toxicity
-Improved PK: Longer half life, AUC